Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enpatoran in COVID-19 pneumonia: Safety and efficacy results from a phase II randomized trial.
McKinnon JE, Santiaguel J, Murta de Oliveira C, Yu D, Khursheed M, Moreau F, Klopp-Schulze L, Shaw J, Roy S, Kao AH; ANEMONE Study Team. McKinnon JE, et al. Among authors: klopp schulze l. Clin Transl Sci. 2023 Dec;16(12):2640-2653. doi: 10.1111/cts.13658. Epub 2023 Oct 23. Clin Transl Sci. 2023. PMID: 37873555 Free PMC article. Clinical Trial.
Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus.
Goteti K, Garcia R, Gillespie WR, French J, Klopp-Schulze L, Li Y, Mateo CV, Roy S, Guenther O, Benincosa L, Venkatakrishnan K. Goteti K, et al. Among authors: klopp schulze l. CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):281-295. doi: 10.1002/psp4.13083. Epub 2023 Dec 4. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38050332 Free PMC article.
Asia-Inclusive Global Development of Enpatoran: Results of an Ethno-Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial.
Klopp-Schulze L, Gopalakrishnan S, Yalkinoglu Ö, Kuroki Y, Lu H, Goteti K, Krebs-Brown A, Nogueira Filho M, Gradhand U, Fluck M, Shaw J, Dong J, Venkatakrishnan K. Klopp-Schulze L, et al. Clin Pharmacol Ther. 2024 Jun;115(6):1346-1357. doi: 10.1002/cpt.3216. Epub 2024 Feb 28. Clin Pharmacol Ther. 2024. PMID: 38415785
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8.
Port A, Shaw JV, Klopp-Schulze L, Bytyqi A, Vetter C, Hussey E, Mammasse N, Ona V, Bachmann A, Strugala D, Reh C, Goteti K. Port A, et al. Among authors: klopp schulze l. Pharmacol Res Perspect. 2021 Oct;9(5):e00842. doi: 10.1002/prp2.842. Pharmacol Res Perspect. 2021. PMID: 34414672 Free PMC article. Clinical Trial.
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups.
Mueller-Schoell A, Michelet R, Klopp-Schulze L, van Dyk M, Mürdter TE, Schwab M, Joerger M, Huisinga W, Mikus G, Kloft C. Mueller-Schoell A, et al. Among authors: klopp schulze l. Cancers (Basel). 2021 May 18;13(10):2432. doi: 10.3390/cancers13102432. Cancers (Basel). 2021. PMID: 34069810 Free PMC article.
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach.
Mueller-Schoell A, Klopp-Schulze L, Schroth W, Mürdter T, Michelet R, Brauch H, Huisinga W, Joerger M, Neven P, Koolen SLW, Mathijssen RHJ, Copson E, Eccles D, Chen S, Chowbay B, Tfayli A, Zgheib NK, Schwab M, Kloft C. Mueller-Schoell A, et al. Among authors: klopp schulze l. Clin Pharmacol Ther. 2020 Sep;108(3):661-670. doi: 10.1002/cpt.1960. Epub 2020 Jul 23. Clin Pharmacol Ther. 2020. PMID: 32578187
15 results